Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Myelodysplastic Syndromes 1Lymphoma, Follicular 1Leukemia, Myeloid, Acute 1Leukemia, Large Granular Lymphocytic 1

Interventions

Peripheral Blood Stem Cell Transplantation 3fludarabine phosphate 2Whole-Body Irradiation 2Mycophenolic Acid 2Cyclosporine 2liposomal doxorubicin 1flt3 ligand protein 1ethanolamine oleate 1cc-486 1Trimethoprim, Sulfamethoxazole Drug Combination 1Trimethoprim 1Thrombopoietin 1Sulfamethoxazole 1Stem Cell Factor 1Sodium Chloride 1Sensitivity and Specificity 1Saline Solution, Hypertonic 1Saline Solution 1Rituximab 1Pentetic Acid 1Ifosfamide 1Filgrastim 1Ethanol 1Edetic Acid 1Docetaxel 1Carboplatin 1Brentuximab Vedotin 1Bortezomib 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Leukemia, Large Granular Lymphocytic × cc-486 × Clear all
NCT05141682 2026-03-03

Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia

Ohio State University Comprehensive Cancer Center

Phase 1/2 Active not recruiting
11 enrolled
Other hematologic neoplasm

Leukemia, Large Granular Lymphocytic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡